These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28676659)

  • 1. Mutations in BRCA2 and taxane resistance in prostate cancer.
    Nientiedt C; Heller M; Endris V; Volckmar AL; Zschäbitz S; Tapia-Laliena MA; Duensing A; Jäger D; Schirmacher P; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Sci Rep; 2017 Jul; 7(1):4574. PubMed ID: 28676659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
    Gallagher DJ; Cronin AM; Milowsky MI; Morris MJ; Bhatia J; Scardino PT; Eastham JA; Offit K; Robson ME
    BJU Int; 2012 Mar; 109(5):713-9. PubMed ID: 21756279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kriege M; Jager A; Hooning MJ; Huijskens E; Blom J; van Deurzen CH; Bontenbal M; Collee JM; Menke-Pluijmers MB; Martens JW; Seynaeve C
    Cancer; 2012 Feb; 118(4):899-907. PubMed ID: 21761396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    Pomerantz MM; Spisák S; Jia L; Cronin AM; Csabai I; Ledet E; Sartor AO; Rainville I; O'Connor EP; Herbert ZT; Szállási Z; Oh WK; Kantoff PW; Garber JE; Schrag D; Kibel AS; Freedman ML
    Cancer; 2017 Sep; 123(18):3532-3539. PubMed ID: 28608931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
    Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A
    Eur Urol; 2021 Jun; 79(6):722-733. PubMed ID: 33153817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.
    Hotte SJ
    Future Oncol; 2017 Feb; 13(4):369-379. PubMed ID: 27712093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
    Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
    Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
    Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
    Wysocki PJ; Korski K; Lamperska K; Zaluski J; Mackiewicz A
    Med Sci Monit; 2008 Jul; 14(7):SC7-10. PubMed ID: 18591931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
    Bobbili PJ; Ivanova J; Solit DB; Mettu NB; McCall SJ; Dhawan M; DerSarkissian M; Arondekar B; Chang J; Niyazov A; Lee J; Huq R; Green M; Turski M; Lam P; Muthukumar A; Guo T; Mohan M; Zhang A; Duh MS; Oh WK
    Clin Genitourin Cancer; 2024 Jun; 22(3):102080. PubMed ID: 38653037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.